Increasing IL-18BP amount or activity (a therapeutic option already clinically validated to treat rare systemic auto-inflammatory diseases44) represents interesting pharmacological perspectives to treat MASLD/MASH. Here, IL18BP is linked to metabolic dysfunction-associated steatotic liver disease.